Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases
Abstract Background Considering the considerable prevalence of allergic disease in the general population, an urgent need exists for inactivated SARS-CoV-2 vaccines that can be safely administered to those subjects. Methods This retrospective cohort study including 1926 participants who received ina...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-05-01
|
| Series: | Respiratory Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12931-022-02054-1 |
| _version_ | 1811253610920542208 |
|---|---|
| author | Chao Cao Feng Qiu Chengcheng Lou Lingling Fang Fang Liu Jingjing Zhong Weijie Sun Weiping Ding Xiaopin Yu Qinhong Xu Ran Wang Liemin Ruan Qifa Song |
| author_facet | Chao Cao Feng Qiu Chengcheng Lou Lingling Fang Fang Liu Jingjing Zhong Weijie Sun Weiping Ding Xiaopin Yu Qinhong Xu Ran Wang Liemin Ruan Qifa Song |
| author_sort | Chao Cao |
| collection | DOAJ |
| description | Abstract Background Considering the considerable prevalence of allergic disease in the general population, an urgent need exists for inactivated SARS-CoV-2 vaccines that can be safely administered to those subjects. Methods This retrospective cohort study including 1926 participants who received inactivated SARS-CoV-2 vaccines, compared their local and systemic reactions in 7 days after each dose of inactivated SARS-CoV-2 vaccine, and anti–SARS-CoV-2 IgG after vaccination in all participants. Results Pain at the injection site within seven days after the first injection was the most commonly reported local reaction, occurring in 31.0% of the patients with allergic disease and 18.9% in the control group, respectively (P < 0.001). After the first dose, systemic events were more frequently reported in patients with allergic disease than control group (30.2% vs. 22.9%, P < 0.001). After the second dose, systemic events occurred less often, affecting 17.1% of the patients with allergic disease and 11.1% of the control group (P < 0.002). The occurrence of fatigue, vertigo, diarrhea, skin rash, sore throat were the most frequent systemic reactions. Overall, a lower incidence of local and systemic reactive events was observed after the second dose than the first dose in patients with allergic disease and control group. Nearly all participants had positive IgG antibodies, and participants with allergic disease had higher frequencies compared with control group (100.0 vs.99.4%). Conclusions Although local and systemic reactions were more frequently reported in patients with allergic disease than control group, administration of the inactivated SARS-CoV-2 vaccine was safe and well tolerated by all participants; no participants experienced a serious adverse event, and none were hospitalized. Trial registration: Chinese Clinical Trial Registry, ChiCTR2100048549. Registered Jul 10, 2021. |
| first_indexed | 2024-04-12T16:53:50Z |
| format | Article |
| id | doaj.art-6c7ca45aeceb4b94943bf14f0c1dfa10 |
| institution | Directory Open Access Journal |
| issn | 1465-993X |
| language | English |
| last_indexed | 2024-04-12T16:53:50Z |
| publishDate | 2022-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Respiratory Research |
| spelling | doaj.art-6c7ca45aeceb4b94943bf14f0c1dfa102022-12-22T03:24:19ZengBMCRespiratory Research1465-993X2022-05-012311810.1186/s12931-022-02054-1Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseasesChao Cao0Feng Qiu1Chengcheng Lou2Lingling Fang3Fang Liu4Jingjing Zhong5Weijie Sun6Weiping Ding7Xiaopin Yu8Qinhong Xu9Ran Wang10Liemin Ruan11Qifa Song12Department of Respiratory and Critical Medicine, Ningbo First HospitalDepartment of Respiratory and Critical Medicine, Ningbo First HospitalDepartment of Respiratory and Critical Medicine, Ningbo First HospitalDepartment of Respiratory and Critical Medicine, Ningbo First HospitalDepartment of Respiratory and Critical Medicine, Ningbo First HospitalDepartment of Respiratory and Critical Medicine, Ningbo First HospitalDepartment of Clinical Laboratory, Ningbo First HospitalDepartment of Respiratory and Critical Medicine, Ningbo First HospitalDepartment of Prevention and Healthy Care, Ningbo First HospitalDepartment of Nursing, Ningbo First HospitalDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical UniversityDepartment of Mental Health, Ningbo First HospitalDepartment of Central Laboratory, Ningbo First HospitalAbstract Background Considering the considerable prevalence of allergic disease in the general population, an urgent need exists for inactivated SARS-CoV-2 vaccines that can be safely administered to those subjects. Methods This retrospective cohort study including 1926 participants who received inactivated SARS-CoV-2 vaccines, compared their local and systemic reactions in 7 days after each dose of inactivated SARS-CoV-2 vaccine, and anti–SARS-CoV-2 IgG after vaccination in all participants. Results Pain at the injection site within seven days after the first injection was the most commonly reported local reaction, occurring in 31.0% of the patients with allergic disease and 18.9% in the control group, respectively (P < 0.001). After the first dose, systemic events were more frequently reported in patients with allergic disease than control group (30.2% vs. 22.9%, P < 0.001). After the second dose, systemic events occurred less often, affecting 17.1% of the patients with allergic disease and 11.1% of the control group (P < 0.002). The occurrence of fatigue, vertigo, diarrhea, skin rash, sore throat were the most frequent systemic reactions. Overall, a lower incidence of local and systemic reactive events was observed after the second dose than the first dose in patients with allergic disease and control group. Nearly all participants had positive IgG antibodies, and participants with allergic disease had higher frequencies compared with control group (100.0 vs.99.4%). Conclusions Although local and systemic reactions were more frequently reported in patients with allergic disease than control group, administration of the inactivated SARS-CoV-2 vaccine was safe and well tolerated by all participants; no participants experienced a serious adverse event, and none were hospitalized. Trial registration: Chinese Clinical Trial Registry, ChiCTR2100048549. Registered Jul 10, 2021.https://doi.org/10.1186/s12931-022-02054-1SARS-CoV-2VaccineAllergic diseasesSafetyImmunogenicity |
| spellingShingle | Chao Cao Feng Qiu Chengcheng Lou Lingling Fang Fang Liu Jingjing Zhong Weijie Sun Weiping Ding Xiaopin Yu Qinhong Xu Ran Wang Liemin Ruan Qifa Song Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases Respiratory Research SARS-CoV-2 Vaccine Allergic diseases Safety Immunogenicity |
| title | Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases |
| title_full | Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases |
| title_fullStr | Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases |
| title_full_unstemmed | Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases |
| title_short | Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases |
| title_sort | safety of inactivated sars cov 2 vaccines in patients with allergic diseases |
| topic | SARS-CoV-2 Vaccine Allergic diseases Safety Immunogenicity |
| url | https://doi.org/10.1186/s12931-022-02054-1 |
| work_keys_str_mv | AT chaocao safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT fengqiu safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT chengchenglou safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT linglingfang safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT fangliu safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT jingjingzhong safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT weijiesun safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT weipingding safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT xiaopinyu safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT qinhongxu safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT ranwang safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT lieminruan safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases AT qifasong safetyofinactivatedsarscov2vaccinesinpatientswithallergicdiseases |